Virbac SA (EPA:VIRP)

Market Cap	3.02B +17.9%
Revenue (ttm)	1.46B +4.8%
Net Income	150.89M +3.9%
EPS	18.00 +3.8%
Shares Out	8.38M
PE Ratio	20.00
Forward PE	17.36
Dividend	1.45 (0.40%)
Ex-Dividend Date	Jun 24, 2025

Volume	1,119
Average Volume	4,206
Open	362.50
Previous Close	360.00
Day's Range	361.00 - 364.00
52-Week Range	296.00 - 389.50
Beta	0.77
RSI	52.81
Earnings Date	Sep 17, 2026

About Virbac

Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at risk of fleas, ticks, lice, and sandflies; Zenidog/Zenifel offers a fogger, spray, and non-electric ph...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1968
• Employees: 6,442
• Stock Exchange: Euronext Paris
• Ticker Symbol: VIRP

Financial Performance

In 2025, Virbac's revenue was 1.46 billion, an increase of 4.82% compared to the previous year's 1.40 billion. Earnings were 150.89 million, an increase of 3.85%.